CIK 0001720893 · Non-accelerated filer<br>Smaller reporting company
BioXcel Therapeutics, Inc.
Sign in to watch- Ticker
- BTAIQ
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821386754
- Phone
- 203-643-8060
- Business address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 33 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-16 | Yocca Frank Chief Scientific Officer | Sale 10b5-1 | −355 | $0.69 | $245 | 14,203 |
| 2024-09-16 | Mehta Vimal CEO and President | Sale 10b5-1 | −832 | $0.69 | $573 | 52,816 |
| 2024-09-16 | Mehta Vimal CEO and President | Sale 10b5-1 | −1,150 | $0.69 | $794 | 51,666 |
| 2024-09-16 | Steinhart Richard I Chief Financial Officer | Sale 10b5-1 | −356 | $0.69 | $246 | 6,204 |
| 2024-09-16 | Rodriguez Javier See Remarks | Sale 10b5-1 | −345 | $0.69 | $238 | 9,133 |
| 2024-09-16 | O'Neill Vincent See Remarks | Sale 10b5-1 | −138 | $0.69 | $95 | 3,907 |
| 2024-09-16 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 | −215 | $0.69 | $149 | 4,033 |
| 2024-09-15 | Yocca Frank Chief Scientific Officer | Option exercise 10b5-1 | +563 | 14,558 | ||
| 2024-09-15 | Yocca Frank Chief Scientific Officer | Option exercise · Restricted Stock Units 10b5-1 | −563 | 5,625 | ||
| 2024-09-15 | Mehta Vimal CEO and President | Option exercise 10b5-1 | +3,500 | 53,648 | ||
| 2024-09-15 | Mehta Vimal CEO and President | Option exercise · Restricted Stock Units 10b5-1 | −3,500 | 35,000 | ||
| 2024-09-15 | Steinhart Richard I Chief Financial Officer | Option exercise 10b5-1 | +563 | 6,560 | ||
| 2024-09-15 | Steinhart Richard I Chief Financial Officer | Option exercise · Restricted Stock Units 10b5-1 | −563 | 5,625 | ||
| 2024-09-15 | Rodriguez Javier See Remarks | Option exercise 10b5-1 | +563 | 9,478 | ||
| 2024-09-15 | Rodriguez Javier See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −563 | 5,625 | ||
| 2024-09-15 | Wiley Matthew T. Chief Commercial Officer | Option exercise 10b5-1 | +750 | 4,248 | ||
| 2024-09-15 | Wiley Matthew T. Chief Commercial Officer | Option exercise · Restricted Stock Units 10b5-1 | −750 | 7,500 | ||
| 2024-09-14 | Yocca Frank Chief Scientific Officer | Option exercise 10b5-1 | +521 | 13,995 | ||
| 2024-09-14 | Yocca Frank Chief Scientific Officer | Option exercise · Restricted Stock Units 10b5-1 | −521 | 3,127 | ||
| 2024-09-14 | Mehta Vimal CEO and President | Option exercise 10b5-1 | +2,609 | 50,148 |
Page 11 of 27 · 521 trades